|
1
|
Loehrer P, Turner S, Kubilis P, et al:
Prospective randomized trial of fluorouracil versus fluorouracil
plus cisplatin in the treatment of metastatic colorectal cancer: a
Hoosier Oncology Group trial. J Clin Oncol. 6:642–648. 1988.
|
|
2
|
Welsh J, Hobbs S and Aherne G: Expression
of uracil DNA glcocylase does not affect cellular sensitivity to
thymidylate synthase (TS) inhibition. Eur J Cancer. 39:378–387.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kehler S and Ladner R: Small interfering
RNA-mediated suppression of dUTPase sensitizes cancer cells to
thymidylate synthase inhibition. Mol Pharmacol. 66:620–626.
2004.PubMed/NCBI
|
|
4
|
Longley D, Harkin D and Johnston P:
5-Fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Waytt M and Wilson D III: Participation of
DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci.
66:788–799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li L, Morales J, Veigl M, et al: DNA
mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the
potential for new therapeutic targets. Br J Pharmacol. 158:679–692.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meyers M, Hwang A, Wagner M, et al: A role
for DNA mismatch repair in sensing and responding to
fluoropyrimidine damage. Oncogene. 22:7376–7388. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lindahl T: An N-glycosidase from
Escherichia coli that releases free uracil from DNA
containing deaminated cytosine residues. Proc Natl Acad Sci USA.
71:3649–3653. 1974.PubMed/NCBI
|
|
9
|
Fujinaka Y, Matsuoka K, Iimori M, et al:
ATR-Chk1 signaling pathway and homologous recombinational repair
protect cells from 5-fluorouracil cytotoxicity. DNA Repair.
11:247–258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kraakman M, Overkamp W, Lange R, et al:
Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis
and a higher frequency of spontaneous deletions. Mol Cell Biol.
22:669–679. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wiegant W, Overmeer R, Godthelp B, van
Buul P and Zdzienicka M: Chinese hamster cell mutant, V-C8, a model
for analysis of Brca2 function. Mutat Res. 600:79–88. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kondo N, Takahashi A, Mori E, et al:
FANCD1/BRCA2 plays predominant role in the repair of DNA
damage induced by ACNU or TMZ. PLoS One. 6:e196592011. View Article : Google Scholar
|
|
13
|
Kondo N, Takahashi A, Mori E, et al: DNA
ligase IV as a new molecular target for temozolomide. Biochem
Biophys Res Commun. 387:656–660. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takahashi A, Matsumoto H, Nagayama K, et
al: Evidence for the involvement of double-strand breaks in
heat-induced cell killing. Cancer Res. 64:8839–8845. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bruun D, Folias A, Akkari Y, et al: siRNA
depletion of BRCA1 but not BRCA2, causes increased genome
instability in Fanconi anemia cells. DNA Repair. 2:1007–1013. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamakawa N, Takahashi A, Mori E, et al:
High LET radiation enhances apoptosis in mutated p53 cancer
cells through caspase-9 activation. Cancer Sci. 99:1455–1460. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lauren S, Pawel J, Miral D and James T:
Linking uracil base excision repair and 5-fluorouracil toxicity in
yeast. Nucleic Acids Res. 34:140–151. 2004.
|
|
18
|
Raafat A, Ekram M and Jachen D: Targeting
DNA double-strand break repair: is it the right way for sensitizing
cells to 5-fluorouracil? Anticancer Drugs. 40:160–170.
2010.PubMed/NCBI
|
|
19
|
Rothkamm K and Lobrich M: Evidence for a
lack of DNA double-strand break repair in human cells exposed to
very low x-ray doses. Proc Natl Acad Sci USA. 100:5057–5062. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takahashi A and Ohnishi T: Does γH2AX
focus formation depend on the presence of DNA double strand breaks?
Cancer Lett. 229:171–179. 2005.
|
|
21
|
Jackson SP: Sensing and repairing DNA
double-strand breaks. Carcinogenesis. 23:687–696. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kanar R, Hoeijimakers JH and Van Gent DC:
Molecular mechanisms of DNA double-strand break repair. Trends Cell
Biol. 8:483–489. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rothkamm K, Kruger I, Thompson LH and
Lobrich M: Pathways of DNA double-strand break repair during the
mammalian cell cycle. Mol Cell Biol. 23:5706–5715. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hinz JM, Yamada NA, Salazar EP, Tebbs RS
and Thompson LH: Influence of double-strand-break repair pathways
on radiosensitivity throughout the cell cycle in CHO cells. DNA
Repair. 4:782–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thompson L and Schild D: Homologous
recombinational repair of DNA ensures mammalian chromosome
stability. Mut Res. 477:131–153. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Davies A, Masson J, McIlwraith M and
Stasiak A and Stasiak A: Role of BRCA2 in control of the RAD 51
recombination and DNA repair protein. Mol Cell. 7:273–282. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ottini L, Masala G, D’Amico C, et al:
BRCA1 and BRCA2 mutation status and tumor
characteristics in male breast cancer: a population-based study in
Italy. Cancer Res. 63:342–347. 2003.
|
|
28
|
Schrader K, Hurlburt J, Kalloger S, et al:
Germline BRCA1 and BRCA2 mutations in ovarian cancer:
utility of a histology-based referral strategy. Obstet Gynecol.
120:235–240. 2012.
|
